Biora Therapeutics, Inc. (BIOR)
(Real Time Quote from BATS)
$0.55 USD
-0.02 (-3.17%)
Updated Oct 8, 2024 02:17 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Biora Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 15 | 30 | 88 | 92 | 33 |
Receivables | 1 | 1 | 1 | 13 | 23 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 12 | 11 |
Other Current Assets | 3 | 7 | 9 | 9 | 8 |
Total Current Assets | 19 | 38 | 98 | 126 | 75 |
Net Property & Equipment | 1 | 2 | 4 | 18 | 16 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 6 | 6 | 6 | 10 | 11 |
Deposits & Other Assets | 3 | 6 | 0 | 0 | 0 |
Total Assets | 31 | 54 | 109 | 154 | 102 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 9 | 17 | 16 |
Current Portion Long-Term Debt | 2 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 1 |
Accrued Expenses | 17 | 16 | 34 | 55 | 84 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 41 | 4 | 19 | 0 | 0 |
Total Current Liabilities | 63 | 23 | 62 | 73 | 100 |
Mortgages | 0 | 0 | 0 | 3 | 3 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 44 | 128 | 126 | 159 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 26 | 5 | 6 | 27 | 82 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 133 | 156 | 194 | 261 | 186 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 869 | 744 | 723 | 453 | 283 |
Retained Earnings | -951 | -827 | -789 | -541 | -348 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 19 | 19 | 19 | 19 | 19 |
Total Shareholder's Equity | -101 | -102 | -85 | -107 | -84 |
Total Liabilities & Shareholder's Equity | 31 | 54 | 109 | 154 | 102 |
Total Common Equity | -101 | -102 | -85 | -107 | -84 |
Shares Outstanding | 27.80 | 8.90 | 6.50 | 2.10 | NA |
Book Value Per Share | -3.65 | -11.49 | -13.07 | -50.95 | 0.00 |
Fiscal Year End for Biora Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 5 | 11 | 15 | 13 |
Receivables | NA | 1 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 2 | 3 | 6 |
Total Current Assets | NA | 9 | 14 | 19 | 19 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 6 | 6 | 6 | 6 |
Deposits & Other Assets | NA | 1 | 0 | 3 | 6 |
Total Assets | NA | 18 | 23 | 31 | 35 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 8 | 5 | 3 | 4 |
Current Portion Long-Term Debt | NA | 2 | 2 | 2 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 20 | 17 | 17 | 24 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 17 | 27 | 41 | 41 |
Total Current Liabilities | NA | 46 | 51 | 63 | 70 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 44 | 43 | 44 | 80 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 29 | 26 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 108 | 123 | 133 | 153 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 878 | 874 | 869 | 836 |
Retained Earnings | NA | -949 | -955 | -951 | -936 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 19 | 19 | 19 | 19 |
Total Shareholder's Equity | NA | -89 | -100 | -101 | -119 |
Total Liabilities & Shareholder's Equity | NA | 18 | 23 | 31 | 35 |
Total Common Equity | 0 | -89 | -100 | -101 | -119 |
Shares Outstanding | 36.70 | 35.80 | 35.80 | 27.80 | 23.40 |
Book Value Per Share | 0.00 | -2.49 | -2.80 | -3.65 | -5.08 |